Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Net Income for 10 consecutive years, with $12.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 134.04% year-over-year to $12.2 million, compared with a TTM value of $83.2 million through Dec 2025, up 178.88%, and an annual FY2025 reading of $83.2 million, up 178.88% over the prior year.
  • Net Income was $12.2 million for Q4 2025 at Zevra Therapeutics, up from -$544000.0 in the prior quarter.
  • Across five years, Net Income topped out at $74.7 million in Q2 2025 and bottomed at -$35.7 million in Q4 2024.
  • Average Net Income over 5 years is -$5.3 million, with a median of -$4.9 million recorded in 2022.
  • The sharpest move saw Net Income surged 622.12% in 2021, then plummeted 674.39% in 2024.
  • Year by year, Net Income stood at -$2.7 million in 2021, then skyrocketed by 340.58% to $6.5 million in 2022, then tumbled by 405.89% to -$19.9 million in 2023, then plummeted by 79.67% to -$35.7 million in 2024, then surged by 134.04% to $12.2 million in 2025.
  • Business Quant data shows Net Income for ZVRA at $12.2 million in Q4 2025, -$544000.0 in Q3 2025, and $74.7 million in Q2 2025.